Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity

Monday, September 18, 2023 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: EDP-323, an oral L-protein inhibitor, has shown positive results in a Phase 1 study for treating respiratory syncytial virus (RSV). The study involved healthy subjects and demonstrated a favorable safety profile. Additionally, the in vitro antiviral activity of EDP-323 aligns with the clinical outcomes observed in the trial.
Price reaction · baseline $12.73 (2023-09-15 close) · hit pre-market · clean, no other ENTA news in the window
day 0 close
-0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • EDP-323 shows promise as a first-in-class treatment for RSV.
  • The Phase 1 study results indicate a favorable safety profile.
  • In vitro antiviral activity correlates with clinical findings.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EDP-323?

EDP-323 is a first-in-class, once-daily oral L-protein inhibitor for RSV.

What were the results of the Phase 1 study?

The Phase 1 study showed a favorable safety profile for EDP-323.

How does EDP-323 work against RSV?

EDP-323 targets the L-protein of RSV, inhibiting its replication.

What is the significance of the in vitro activity?

The in vitro antiviral activity of EDP-323 correlates with clinical findings.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EDP-323 RSV Phase 1 study L-protein inhibitor
Last updated: Sep 18, 2023

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →